]>
IRCT138812222602N2 IRCT 2010-03-13 Iran University of Medical Sciences Effects of lipoic acid on inflammation and antioxidant factors in multiple sclerosis Effect of lipoic acid on antioxidant factors, Th1/Th2 balance and clinical signs in multiple sclerosis patients 2010-09-02 anticipated 60 Complete https://irct.ir/trial/2373 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive. 2-3 muiltiple sclerosis. Intervention 1: lipoic acid supplement (1200mg/day) for 90 days. Intervention 2: control group: 2 capsuls including dietary fiber.
public Dr. Shahriar Eghtesadi
School of Health, Alvand Ave, Arjanteen Square
Tehran Iran (Islamic Republic of) +98 21 8877 9118 egtesadi@iums.ac.ir, egtesadi@yahoo.com School of Health, Iran University of Medical Sciences scientific Dr Shahriar Eghtesadi
School of Health, Alvand Ave, Arjanteen Square
Tehran Iran (Islamic Republic of) +98 21 8877 9118 egtesadi@iums.ac.ir, eghtesadi@yahoo.com School of Health, Iran University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: age 18-51 years, able to provide informed consent and diagnosed with relapsing remitting MS. Exclusion criteria: MS exacerbation during the study, systemically administered corticosteroids during the study , pregnant or breast-feeding , other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus and other autoimmune disease) that might increase the risk of subject experiencing adverse events. Consumption of vitamin, mineral and antioxidant supplement 30 days before study entry, Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study and compliance less than 70%. 18 years 51 years Both G35 Multiple sclerosis Treatment - Drugs Placebo lipoic acid supplement (1200mg/day) for 90 days control group: 2 capsuls including dietary fiber Decrease serum lipoic acid concentration. Timepoint: 12 week. Method of measurement: HPLC. Decrease serum TNF-a concentration. Timepoint: 12 week. Method of measurement: labratory kit. Decrease serum MDA concentration. Timepoint: 12 week. Method of measurement: Spectrophotometry. Increase SOD. Timepoint: 12 week. Method of measurement: Spectrophotometry. Increase glutathione peroxidase. Timepoint: 12 week. Method of measurement: Spectrophotometry. Decrease serum ADA concentration. Timepoint: 12 week. Method of measurement: ELYSA. Decrease serum INF-y concentration. Timepoint: 12 week. Method of measurement: ELYSA. Increase TGF-B. Timepoint: 12 week. Method of measurement: ELYSA. Increase IL-6. Timepoint: 12 week. Method of measurement: ELYSA. Increase IL-4. Timepoint: 12 week. Method of measurement: ELYSA. Decrease MMP-9. Timepoint: 12 week. Method of measurement: ELYSA. Decrease VCAM-1. Timepoint: 12 week. Method of measurement: ELYSA. Decrease ICAM-1. Timepoint: 12 week. Method of measurement: ELYSA. TAC. Timepoint: 12 week. Method of measurement: colorimetry. Decrease EDSS. Timepoint: 12 week. Method of measurement: observation. Iran University of Medical Sciences Approved 2010-07-19 School of Health, Iran University of Medical Sciences Alvand Ave, Arjanteen Square Tehran Iran (Islamic Republic of)